Skip to main content

Table 3 Post-index healthcare utilization while persistent on antifibrotics

From: Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study

  All Patients Pirfenidone Nintedanib P Value1
N = 1248 N = 697 N = 551
Follow-Up
 Days of follow-up after index date, mean (SD) 247.0 (243.7) 260.7 (251.1) 229.6 (233.0) 0.025
All-cause utilization
 Inpatient hospitalization2, n (%) 271 (21.7) 172 (24.7) 99 (18.0) 0.004
  Inpatient hospitalizations PPPM, mean (SD) 0.06 (0.17) 0.06 (0.18) 0.05 (0.16) 0.208
  Length of stay, mean (SD), days 5.0 (4.1) 4.8 (3.4) 5.4 (5.1) 0.239
   Median 4 4 4  
 Any outpatient visit, n (%) 1195 (95.8) 666 (95.6) 529 (96.0) 0.692
  Emergency department visit 308 (24.7) 174 (25.0) 134 (24.3) 0.793
   Visits PPPM, mean (SD) 0.07 (0.23) 0.07 (0.20) 0.08 (0.26) 0.163
  Physician office visit 1092 (87.5) 613 (87.9) 479 (86.9) 0.590
   Visits PPPM, mean (SD) 1.2 (1.0) 1.2 (1.0) 1.2 (1.0) 0.724
 Pharmacy, n (%) 1248 (100.0) 697 (100.0) 551 (100.0) 1.000
  Medication claims PPPM, mean (SD) 4.3 (2.6) 4.2 (2.5) 4.3 (2.7) 0.335
Respiratory-related utilization
 Inpatient hospitalization2, n (%) 146 (11.7) 97 (13.9) 49 (8.9) 0.006
  Inpatient hospitalizations PPPM, mean (SD) 0.03 (0.13) 0.03 (0.14) 0.02 (0.11) 0.166
  Length of stay, mean (SD), days 5.3 (5.4) 4.6 (3.2) 6.5 (8.1) 0.052
   Median 4 4 4  
 Any outpatient visit, n (%) 1147 (91.9) 640 (91.8) 507 (92.0) 0.901
  Emergency department visit 173 (13.9) 101 (14.5) 72 (13.1) 0.470
   Visits PPPM, mean (SD) 0.04 (0.14) 0.03 (0.13) 0.04 (0.16) 0.196
  Physician office visit 1025 (82.1) 577 (82.8) 448 (81.3) 0.499
   Visits PPPM, mean (SD) 0.68 (0.63) 0.68 (0.65) 0.67 (0.60) 0.913
 Pharmacy, n (%) 1248 (100.0) 697 (100.0) 551 (100.0) 1.000
  Medication claims PPPM, mean (SD) 1.4 (0.7) 1.4 (0.7) 1.5 (0.8) 0.026
  1. PPPM per-person per-month, SD standard deviation
  2. 1 Pirfenidone vs. nintedanib
  3. 2 Excluding inpatient hospitalizations for a lung transplant